Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q2 EPS of ($0.24), $0.03 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $180 thousand versus the consensus estimate of $257.6 thousand.

For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.